₹590
(Inclusive of all Taxes)
₹88.5 Cashback (15%)
coupon
Prescription drugWhats That
Composition :
Manufacturer/Marketer :
Consume Type :
Return Policy :
Expires on or after :
Secure Payment
Trusted by 8 Crore Indians
Genuine Products
Author Details
Disclaimer
Customers Also Bought
Alcohol
Unsafe
You should avoid consuming alcohol with Invokana 100 mg Tablet as it may alter your blood sugar levels or lead to serious side effects.
Pregnancy
Caution
No sufficient data are available on the use of Invokana 100 mg Tablet in pregnancy. Invokana 100 mg Tablet is a Category C pregnancy drug that is not recommended for use in pregnancy. Hence, consult your doctor before taking this medicine.
Breast Feeding
Caution
There is no sufficient data on how Invokana 100 mg Tablet affects breastfeeding. It is safe to seek medical advice before you start Invokana 100 mg Tablet if you are breastfeeding.
Driving
Caution
Invokana 100 mg Tablet is safe to take before driving as it does not affect your thinking ability. Do not drive or operate machinery if you experience dizziness or drowsiness.
Liver
Caution
If you have liver disease or a history of liver impairment, consult your doctor before taking Invokana 100 mg Tablet . Your doctor may adjust the dose or prescribe a suitable alternative based on your condition.
Kidney
Caution
If you have kidney disease or a history of kidney impairment, consult your doctor before taking Invokana 100 mg Tablet . Your doctor may adjust the dose or prescribe a suitable alternative based on your condition.
Children
Caution
Invokana 100 mg Tablet is not recommended for children below 18 years of age, as the safety and effectiveness were not established.
Product Substitutes
Drug-Drug Interactions
Drug-Drug Interactions
Login/Sign Up
Co-administration of Invokana 100 mg Tablet with Gatifloxacin may affect blood glucose levels. Both low blood glucose and, less frequently, high blood glucose have been reported.
How to manage the interaction:
Although there is a possible interaction, Invokana 100 mg Tablet can be taken with Gatifloxacin if prescribed by the doctor. Consult the prescriber if you experience symptoms such as nervousness, confusion, headache, dizziness, drowsiness, tremors, nausea, hunger, weakness, perspiration, palpitation, rapid heartbeat, increased urination, increased thirst, and increased hunger. Maintaining blood glucose levels is advised. Do not discontinue the medication without consulting a doctor.
Co-administration of Morphine with Invokana 100 mg Tablet may increase the blood levels and side effects of morphine.
How to manage the interaction:
Co-administration of Morphine with Invokana 100 mg Tablet can result in an interaction, but it can be taken if a doctor has advised it. However, if you experience any symptoms like trouble breathing, feeling tired, or having a cough, dizziness, drowsiness, difficulty concentrating, impaired judgment, reaction speed, and motor coordination, make sure to contact a doctor immediately. Do not stop using any medications without consulting a doctor.
Drug-Food Interactions
Drug-Food Interactions
Login/Sign Up
Drug-Diseases Interactions
Drug-Diseases Interactions
Login/Sign Up
Due to a lack of clinical data, the SGLT2 inhibitors ertugliflozin and Invokana 100 mg Tablet are not advised for use in patients with severe hepatic impairment. It is advised to exercise caution when using dapagliflozin in patients with severe hepatic impairment. Patients with mild or moderate hepatic impairment do not require dosage modifications.
How to manage the interaction:
Invokana 100 mg Tablet is not recommended for use in patients with severe hepatic impairment due to a lack of clinical data.
In patients with deteriorating renal function, the glucose-lowering benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors are reduced. In addition, those who have impaired renal function (eGFR less than 60 mL/min/1.73 m2), those who are elderly, and those on loop diuretics may be more susceptible to deleterious effects of volume depletion like hypotension and acute kidney injury.
How to manage the interaction:
The glucose-lowering effects of the medicine may be decreased in patients with worsening kidney function. Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics . Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.
How to manage the interaction:
Low blood pressure might occur in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics. Patients should be monitored during therapy.
The usage of sodium-glucose cotransporter 2 (SGLT-2) inhibitors has been linked to an increased risk of genital mycotic infections. When administering this medication to patients who have a history of genital mycotic infections or who have not undergone circumcision, caution should be taken because they are more susceptible to experience genital mycotic infections. Observe and treat as necessary.
How to manage the interaction:
Genital mycotic infections may occur. Care should be exercised in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections. Monitoring the patient for infections is advised.
Have a query?